Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Beryl Drugs Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts Beryl Drugs Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Beryl Drugs - PROCEEDINGS OF EGM
-
Beryl Drugs - ANNOUNCEMENT UBDER REGULATION 44 VOTING RESULTS OF EGM HELD ON 11TH MAY 2026
-
Beryl Drugs - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
-
Beryl Drugs - ANNOUNCEMENT UNDER REGULATION 30
-
Beryl Drugs - Announcement Under Regulation 30
-
Beryl Drugs - Announcement under Regulation 30 (LODR)-Change in Management
-
Beryl Drugs - Announcement under Regulation 30 (LODR)-Change in Management
-
Beryl Drugs - Shareholder Meeting / Postal Ballot-Outcome of EGM
-
Beryl Drugs has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Beryl Drugs - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Beryl Drugs - COMPLIANCE CERTIFICATE
-
Beryl Drugs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Beryl Drugs - FIXES RECORD DATE FOR THE PURPOSE OF EXTRA ORDINARY GENERAL MEETING OF THE COMPANY
-
Beryl Drugs - INTIMATION OF E-VOTING DATES FOR THE PURPOSE OF EOGM OF THE COMPANY
-
Beryl Drugs - EGM ON 11TH MAY, 2026 AT 11:00 A.M
-
Beryl Drugs - FIXES RECORD DATE FOR THE PURPOSE OF EXTRA ORDINARY GENERAL MEETING
-
Beryl Drugs - Board Meeting Outcome for OUTCOME OF BOARD MEETING
-
Beryl Drugs - DISCLOSURE UNDER REGULATION 7(2) OF SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015
-
Beryl Drugs - DISCLOSURE UNDER REGULATION 29(2) OF SEBI(SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011
-
Beryl Drugs - DISCLOUSRE UNDER REGULATION 7(2) OF SEBI(PROHIBITION OF INSIDER TRADING )REGULATIONS, 2015
-
Beryl Drugs - DISCLOSURE UNDER REGULATION 29(2) UNDER SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVER) REGULATIONS, 2011
-
Beryl Drugs - DISCLOSURE UNDER REGULATION 7(2) OF SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015
-
Beryl Drugs - DISCLOSURE UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS)REGULATIONS, 2011
-
Beryl Drugs - Board Meeting Intimation for Consider And Approve The Date And Notice Of Extra Ordinary General Meeting (EOGM)
-
Beryl Drugs - SUBMISSION OF DISCLOSURE UNDER REGULATION 7(2)
-
Beryl Drugs - SUBMISSION OF DISCLOSURE UNDER REGULATION 29(2)
-
Beryl Drugs - Regulations 7 (2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015
-
Beryl Drugs - Submission Of Disclosure Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations
-
Beryl Drugs - Submission Of Disclosure Under Regulations 7 (2) Of Securities And Exchange Board Of India (Prohibition Of Insi
-
Beryl Drugs - Submission Of Disclosure Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations
-
Beryl Drugs - Submission Of Disclosure Under Regulations 7 (2) Of Securities And Exchange Board Of India (Prohibition Of Insi
-
Beryl Drugs - Submission Of Disclosure Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations
-
Beryl Drugs - Submission Of Disclosure Under Regulations 7 (2) Of Securities And Exchange Board Of India (Prohibition Of Insi
-
Beryl Drugs - Submission Of Disclosure Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations
Key fundamentals
Evaluate the intrinsic value of Beryl Drugs Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 13.5773 | 14.0172 | 12.6085 | 12.5872 | 12.2693 |
| Liabilities | 13.5773 | 14.0172 | 12.6085 | 12.5872 | 12.2693 |
| Equity | 5.0937 | 5.0937 | 5.0937 | 5.0937 | 5.0936 |
| Gross Profit | 1.2324 | 2.2788 | 1.9451 | 0.408 | 1.4482 |
| Net Profit | 0.5788 | 0.7686 | 0.766 | -0.659 | 0.2396 |
| Cash From Operating Activities | 2.6366 | 0.8203 | 2.4804 | -0.2867 | 0.3777 |
| NPM(%) | 2.73 | 2.87 | 2.84 | -4.51 | 1.7 |
| Revenue | 21.1462 | 26.7296 | 26.8878 | 14.6037 | 14.0929 |
| Expenses | 19.9138 | 24.4508 | 24.9427 | 14.1957 | 12.6446 |
| ROE(%) | 6.23 | 8.28 | 8.25 | -7.1 | 2.58 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Beryl Drugs Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 723.45 | 2.67 | 0.00 | 12.07 | -26.19 | 0.69 |
| Lotus Eye Hospital and Institute Ltd | 107.00 | -0.60 | 343.74 | 43.98 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 17.37 | 0.00 | 0.00 | 91.33 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 677.75 | 2.87 | 0.00 | 41.48 | -363.15 | 0.00 |
Company Info
1994 -The company was incorporated as a medicine pharmaceutical manufacturer. 2007 -The board of directors of the company at its meeting held on Nov.16, 2007 decided to issue 1.50 million equity shares and 2 million warrants to promoters and other strategic investors on preferential basis. -Board of the company had increased the authorized share capital of the company from Rs 5.50 crores to Rs 10.00 crores. 2008 -Board of directors of the company had approved to issue 35 lacs warrants to promoters and other strategic investors on preferential basis. 2015 -Beryl Drugs, MPPHSCL sign deal worth Rs 11.8 crores.
1994 -The company was incorporated as a medicine pharmaceutical manufacturer. 2007 -The board of directors of the company at its meeting held on Nov.16, 2007 decided to issue 1.50 million equity shares and 2 million warrants to promoters and other strategic investors on preferential basis. -Board of the company had increased the authorized share capital of the company from Rs 5.50 crores to Rs 10.00 crores. 2008 -Board of directors of the company had approved to issue 35 lacs warrants to promoters and other strategic investors on preferential basis. 2015 -Beryl Drugs, MPPHSCL sign deal worth Rs 11.8 crores.
Read More
Parent Organisation
Beryl Drugs Ltd.
Founded
24/08/1993
Managing Director
Mr.Sanjay Sethi
NSE Symbol
FAQ
The current price of Beryl Drugs Ltd is
The 52-week high for Beryl Drugs Ltd is
The market capitalization of Beryl Drugs Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Beryl Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Beryl Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Beryl Drugs Ltd shares.
The CEO of Beryl Drugs Ltd is Mr.Sanjay Sethi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
